Allos Therapeutics to Present at the 2007 RBC Capital Markets Healthcare Conference
05 Dezembro 2007 - 11:00AM
PR Newswire (US)
WESTMINSTER, Colo., Dec. 5 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH), a biopharmaceutical company
focused on the development and commercialization of small molecule
therapeutics for the treatment of cancer, today announced that Paul
L. Berns, President and CEO, will participate on the "Better Drugs
& Novel Approaches To Cancer Therapy" panel at the 2007 RBC
Capital Markets Healthcare Conference in New York. The panel
presentation will take place at 1:30 p.m. (Eastern) on December 13,
2007. There will be a live webcast of the presentation, which will
be accessible through a link posted on the Allos website home page
and investor relations section. The webcast will be available for
replay on Allos' website through December 28, 2007. About Allos
Therapeutics, Inc. Allos Therapeutics is a biopharmaceutical
company focused on the development and commercialization of small
molecule therapeutics for the treatment of cancer. The Company's
lead product candidate, PDX (pralatrexate), is a novel antifolate
currently under evaluation in a pivotal Phase 2 (PROPEL) trial in
patients with relapsed or refractory peripheral T-cell lymphoma.
The PROPEL trial is being conducted under an agreement reached with
the U.S. Food and Drug Administration under its special protocol
assessment, or SPA process. The Company is also investigating PDX
in patients with non-small cell lung cancer and a range of lymphoma
sub-types. The Company's other product candidate is RH1, a targeted
chemotherapeutic agent currently being evaluated in a Phase 1 trial
in patients with advanced solid tumors or non-Hodgkins Lymphoma
(NHL). For additional information, please visit the Company's
website at http://www.allos.com/. Safe Harbor Statement The
anticipated presentation will contain forward-looking statements
that involve significant risks and uncertainties. Additional
information concerning these forward-looking statements and other
factors that may cause actual results to differ materially from
those anticipated in the forward-looking statements is contained in
the "Risk Factors" section of the Company's Annual Report on Form
10-K for the year ended December 31, 2006 and in the Company's
other periodic reports and filings with the Securities and Exchange
Commission. The Company cautions investors not to place undue
reliance on the forward-looking statements contained in the
presentation. All forward-looking statements are based on
information currently available to the Company on the date thereof,
and the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of this presentation, except as required by law.
DATASOURCE: Allos Therapeutics, Inc. CONTACT: Derek Cole, Vice
President, Investor Relations of Allos Therapeutics, Inc.,
+1-720-540-5367, Web site: http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre Allos Therapeutics, Inc. (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Allos Therapeutics (MM)